By preventing the use of hydroxychloroquine in combination with zinc, lives are being lost.
Prior to March 2020, hydroxychloroquine was considered relatively safe, with a rare risk of arrhythmia, but not death.
Hydroxychloroquine, originally used as an antimalarial agent, has beneficial effects on mucocutaneous symptoms in systemic lupus erythematosus. It is also used for the skin rash of discoid lupus erythematosus. A number of rare but serious adverse reactions can occur with its use and are usually associated with long-term therapy.
Beginning in March 2020, after hydroxychloroquine in conjunction with zinc was identified as a possible treatment for COVID-19, hydroxychloroquine suddenly became deadly:
Antimalarials widely used against COVID-19 heighten risk of cardiac arrest.
FDA: Improper use of hydroxychloroquine, chloroquine for COVID-19 may increase risk for arrhythmias, death
Small chloroquine study ends early in Brazil due to deaths
A warning to those considering combination therapy with hydroxychloroquine (HCQ) for COVID-19: individually, some medications being considered have been known to put users at risk of sudden cardiac death, major U.S. medical societies said.
In response to the new hysteria about the danger of hydroxychloroquine, the American College of Cardiology wrote this: